2004
DOI: 10.1016/j.bpa.2003.12.005
|View full text |Cite
|
Sign up to set email alerts
|

The systemic inflammatory response syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
34
0
5

Year Published

2005
2005
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 73 publications
(39 citation statements)
references
References 113 publications
0
34
0
5
Order By: Relevance
“…To explore the mechanisms by which anti-MIF mAbs conferred protection, we discovered that the survival benefit of anti-MIF mAb treatment was associated with a reduction in the host systemic inflammatory responses, as shown by a decrease in the plasma concentrations of TNF-α and IL-6. Moreover, sepsis is also a generalized inflammatory response that involves organs distal to the locus of the initial infectious insult [26]. We discovered that the F11 anti-MIF mAb also protected the lung and kidney tissues of CLP mice.…”
Section: Discussionmentioning
confidence: 92%
“…To explore the mechanisms by which anti-MIF mAbs conferred protection, we discovered that the survival benefit of anti-MIF mAb treatment was associated with a reduction in the host systemic inflammatory responses, as shown by a decrease in the plasma concentrations of TNF-α and IL-6. Moreover, sepsis is also a generalized inflammatory response that involves organs distal to the locus of the initial infectious insult [26]. We discovered that the F11 anti-MIF mAb also protected the lung and kidney tissues of CLP mice.…”
Section: Discussionmentioning
confidence: 92%
“…Sepsis is a generalized inflammatory response, which involves organ systems remote from the locus of the initial infectious insult [1]. One of the underlying mechanisms of sepsis is thought to be the oxidative damage due to the generation of free radicals.…”
Section: Introductionmentioning
confidence: 99%
“…The role of pro-inflammatory (TNF-α, IFN-γ, IL-6) and anti-inflammatory (IL-4, IL-10) biomarkers has exhaustively been researched. However, the optimal treatment for SIRS is complicated by this multi-factorial nature of inciting agents and varied immune response in the clinical setting [4,5].…”
Section: Discussionmentioning
confidence: 99%